You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. VIRUS ISOLATE-BASED HIV-1 RESISTANCE ASSAY

    SBC: Tranzyme, Inc.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  2. Utility of a Novel Anthracycline Analog in Psoriasis

    SBC: GEM Pharmaceuticals            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common immune-mediated disease that affects approximately 2% of the US and European populations and significantly impacts the quality of life. T cells are recognized as primary mediators of the disease and new generation therapies aimed at eliminating reactive T cells or interfering with the immunologic cascade caused by their activation have bee ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Using siRNAs against tau circular RNAs as a rational therapy for Alzheimer's disease

    SBC: CircCure Corporation            Topic: R

    Summary:The formation of neurofibrillary tangles (NFT) formed by aggregation of the microtubule-associated protein tau (MAPT) is a hallmark of Alzheimer’s disease (AD) and the likely cause of neuronal death. Currently, there are no rational treatments available that directly target NFT formation and thus address the direct molecular cause for AD. Based on our academic research, we will develop a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Universal affinity membrane chromatography for rapid, one-step purification of proteins

    SBC: TriAltus Bioscience, LLC            Topic: 400

    Project Summary The goal of this STTR Phase I project is to demonstrate the feasibility of developing the first universal affinity membrane for the rapid, selective, one-step purification of difficult-to-purify proteins. Despite the urgency for expanding the application of gene editing systems and accelerating vaccine and antibody test development, the rapid purification of critical proteins such ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Ultra-soft atomic force microscope (USAFM) technology using nano-cantilevers for

    SBC: NAUGANNEEDLES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): NaugaNeedles LLC in collaboration with researchers from Purdue University are proposing to develop an advanced new Ultra-Soft Atomic Force Microscope (USAFM). This USAFM can gently create images of soft biological samples in buffer solutions with sub-picoNewton (pN) forces and sub-nm lateral resolution. This new AFM technology will have a high-bandwidth to ensu ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Transgenic plant cells as source of hepatoprotective dr*

    SBC: NAPROGENIX, INC.            Topic: N/A

    Transgenic plant cells as source of hepatoprotective drugs. Alcoholic liver damage (ALD) is among the ten most common causes of death in the USA. The liver may be uniquely sensitive because it metabolizes ethanol at a high rate. This generates acetaldehyde intracellularly, damaging cell components directly, and/or inducing apoptotic cell death. Although some plant natural products are protective i ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. Transgenic plant cells as a source of hepatoprotective drugs

    SBC: NAPROGENIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcoholic liver damage (ALD) is among the top ten causes of death in the USA, but existing therapeutic interventions are relatively ineffective. Hepatocytes are susceptible to damage probably because they have a high level of alcohol dehydrogenase (ADH) which metabolizes alcohol to form acetaldehyde and reactive oxygen species (ROS), which are both cytotoxic. C ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. Transdermal Naltrexone for Opiate Addiction and Alcoholism

    SBC: ALLTRANZ, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Transdermal Naltrexone for Opiate Addiction and Alcoholism

    SBC: ALLTRANZ, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Transdermal Cannabidiol Delivery for Alcohol-Induced Neurodegeneration

    SBC: ALLTRANZ, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment of alcohol use disorders (AUDs), commonly referred to as alcoholism, has been hampered by alcohol's promiscuous pharmacological effects and the complex etiology of addiction. People drink in excess for a variety of reasons, and an approach that targets more of these reasons will have greater commercial success than an approach that only targets a sole ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government